GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » EV-to-FCF

NewAmsterdam Pharma Co NV (FRA:KH6) EV-to-FCF : -9.56 (As of May. 14, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NewAmsterdam Pharma Co NV's Enterprise Value is €1,241.90 Mil. NewAmsterdam Pharma Co NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-129.93 Mil. Therefore, NewAmsterdam Pharma Co NV's EV-to-FCF for today is -9.56.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's EV-to-FCF or its related term are showing as below:

FRA:KH6' s EV-to-FCF Range Over the Past 10 Years
Min: -32.61   Med: -21.76   Max: -4.93
Current: -9.47

During the past 4 years, the highest EV-to-FCF of NewAmsterdam Pharma Co NV was -4.93. The lowest was -32.61. And the median was -21.76.

FRA:KH6's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.305 vs FRA:KH6: -9.47

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), NewAmsterdam Pharma Co NV's stock price is €17.80. NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.978. Therefore, NewAmsterdam Pharma Co NV's PE Ratio for today is At Loss.


NewAmsterdam Pharma Co NV EV-to-FCF Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV EV-to-FCF Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - 40.35 -4.11

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial - - 40.35 - -4.11

Competitive Comparison of NewAmsterdam Pharma Co NV's EV-to-FCF

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NewAmsterdam Pharma Co NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's EV-to-FCF falls into.



NewAmsterdam Pharma Co NV EV-to-FCF Calculation

NewAmsterdam Pharma Co NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1241.896/-129.929
=-9.56

NewAmsterdam Pharma Co NV's current Enterprise Value is €1,241.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NewAmsterdam Pharma Co NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-129.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NewAmsterdam Pharma Co NV  (FRA:KH6) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

NewAmsterdam Pharma Co NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=17.80/-1.978
=At Loss

NewAmsterdam Pharma Co NV's share price for today is €17.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.978.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


NewAmsterdam Pharma Co NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines